Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

Phase 1

Active, not recruiting

Conditions: Cutaneous Melanoma

Interventions: Drug: Nivolumab (480 mg infusion)
Biological: NeoVax plus Montanide
Drug: Ipilimumab

Registration Number: NCT03929029

Lead Sponsor: Dana-Farber Cancer Institute

Brief Summary: This research study is investigating a new type of personalized neoantigen vaccine, NeoVax, plus Montanide® in combination with Ipilimumab (Yervoy™) and Nivolumab (Opdivo®) as a possible treatment for cutaneous melanoma.

The drugs involved in this study are:

* Personalized Neoantigen Vaccine

* Poly-ICLC (Hiltonol®)

* Montanide®

* Ipilimumab (Yervoy™)

* Nivolumab (Opdivo®)

Detailed Description: This is a Phase I clinical trial to assess the safety of an investigational personalized neoantigen vaccine, NeoVax, consisting of personalized neoantigen peptides and Hiltonol® plus Montanide®, in combination with Nivolumab and Ipilimumab. The study also seeks to define the appropriate dose of investigational Ipilimumab administered subcutaneously (under the skin) to use for further studies. "Investigational" means that the combination is being studied. The FDA (the U.S. Food and Drug Administration) has not approved personalized neoantigen peptides, Hiltonol®, or Montanide® as a treatment for any disease. The combination is an investigational therapy being developed for use in the treatment of certain cancers. The FDA has approved Nivolumab (Opdivo®) and intravenous Ipilimumab (Yervoy™) as a treatment option for melanoma. Subcutaneous administration of Ipilimumab has not been approved by the FDA for treatment of melanoma.

It is known that melanoma cancers have mutations (changes in genetic material) that are specific to each patient and tumor. These mutations can cause the tumor cells to produce proteins that appear very different from the body's own cells. It is possible that the proteins used in a vaccine may cause strong immune responses, which may help the body fight any tumor cells that could allow the melanoma to come back in the future.

In this study, melanoma cells will be obtained either by tumor surgery or tumor biopsy. The genetic material contained in the melanoma cells will be examined for the presence of tumor-specific mutations. This information will be used to prepare small protein fragments, which are called "peptides". Each NeoVax vaccine will consist of up to 20 peptides mixed with two drugs that activate the immune system called Poly-ICLC (Hiltonol®) and Montanide®.

A 5-patient dose escalation design will be implemented with up to three cohorts of patients. Each cohort of patients (5 patients/cohort) will begin treatment with Nivolumab (480 mg intravenously every 4 weeks). The NeoVax vaccine will be prepared during the initial 12 weeks of Nivolumab therapy. Any patient for whom vaccine cannot be made will be replaced within a cohort. Vaccine will be administered on weeks 12, 15, 18, and 21 with Hiltonol, Montanide, and concurrent Ipilimumab. The protocol specifies that the dose of Ipilimumab will begin at 2.5 mg per injection site. If the number of dose-limiting toxicities (DLTs) occurring within 7 weeks of NeoVax initiation is 0 or 1 (i.e., in no more than 20% of patients) the dose of Ipilimumab will be increased to 5 mg per injection site in the next cohort. If the number of DLTs is 2 or more, the dose of Ipilimumab will be decreased to 1.25 mg per injection site in the next cohort. The maximum tolerated dose (MTD) will be the highest dose of Ipilimumab in which the DLT rate is 20% or less.

Toxicities will be graded using the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE 5.0).

A DLT is defined as:

1. Grade 3 or 4 toxicity that is definitely, probably, or possibly related to administration of vaccine, excluding transient (≤ 72 hours) flu-like symptoms; grade 3 nausea, vomiting, diarrhea, or constipation that returns to grade 2 (or lower) within 48 hours; any grade 3 rash that resolves to grade 2 or lower within 14 days; any grade 3 endocrine abnormality that is corrected with hormonal therapy within 4 weeks.

2. Grade 3 or 4 abnormal laboratory value that is at least possibly related to the administration of vaccine lasting for more than 7 days and requires hospitalization or medical intervention. Excludes any grade 3 electrolyte abnormality that: lasts ≤ 72 hours, is not clinically complicated, and resolves spontaneously or responds to conventional medical intervention.

3. Any grade 3 or grade 4 toxicity that is considered, in the opinion of the Principal Investigator, to be dose-limiting.

4. Any death related to study treatment.

Health status assessments, including physical exams and blood chemistry, will be conducted every 4 weeks. Leukapheresis will occur at the time of enrollment, prior to administration of the first dose of NeoVax, and at week 20. For patients with unresectable melanoma, tumor biopsies will be obtained prior to the first dose of vaccine, at week 20, and at the time of disease progression. Vaccine site biopsies will be obtained at weeks 15 and 18 (i.e., at the times of the second and third vaccine administration).

Recruitment & Eligibility

Status: ACTIVE_NOT_RECRUITING

Sex: All

Target Recruitment: 11

Inclusion Criteria

Participant is willing and able to give written informed consent
Participants must have histologically confirmed cutaneous melanoma that is unresectable stage III or stage IV; at least one site of disease must be resectable, partially-resectable, or amenable to core biopsies to provide tumor tissue for sequence analysis. Participants with mucosal or uveal melanoma are excluded.
Participants must have measurable disease by RECIST v1.1 that has not been treated with local therapy within the last 12 months of study treatment. The measurable lesion and the lesion used for surgical or core biopsies can be identical as long as it remains measurable after biopsy
Age ≥ 18 years
ECOG performance status of 0 or 1
Recovered from all toxicities associated with prior treatment, to acceptable baseline status (as to Lab toxicity see below limits for inclusion) or a National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4, Grade of 0 or 1, except for toxicities not considered a safety risk, such as alopecia or vitiligo
Participants must have normal organ and marrow function as defined below:
- WBC ≥3,000/µL
- ANC ≥1,500/µL
- Platelets ≥100,000/µL
- Hemoglobin ˃ 9.0 g/dL
- Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
- AST(SGOT)/ALT(SGPT) ≤ 3 x ULN
- Creatinine ≤ 1.5 x ULN OR
- Creatinine clearance ≥40 mL/min/1.73 m2 for participants with creatinine levels above institutional normal (if using the Cockcroft-Gault formula below):
- Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL
- Male CrCl = (140 - age in years) x weight in kg x 1.00 72 x serum creatinine in mg/dL
Women of childbearing potential (WOCBP) should have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of Nivolumab, because the effects of NeoVax plus Montanide and Nivolumab on the developing human fetus are unknown
Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with study agents, breastfeeding should be discontinued if the mother is treated with Ipilimumab, Nivolumab and Personalized Neoantigen vaccine + Montanide.
Female participants enrolled in the study, who are not free from menses for >2 years, post hysterectomy / oophorectomy, or surgically sterilized, should be willing to use either 2 adequate barrier methods or a barrier method plus a hormonal method of contraception to prevent pregnancy or to abstain from sexual activity throughout the study, starting with visit 1 through 23 weeks (30 days plus the time required for Nivolumab to undergo five half-lives) after the last dose of study therapy. Approved contraceptive methods include for example: intra uterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, or female condom with spermicide. Spermicides alone are not an acceptable method of contraception. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.
Male participants should agree to use an adequate method of contraception starting with visit 1 through 31 weeks after the last dose of study therapy
Eligibility Criteria for Secondary Registration
ECOG performance status of 0 or 1
Screening laboratory values must meet the following criteria and should be obtained within 7 days prior to registration
- WBC ≥ 3000/μL
- Neutrophils ≥ 1500/μL
- Platelets ≥ 100 x103/μL
- Hemoglobin > 9.0 g/dL
- Serum creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min (if using the Cockcroft-Gault formula below):
- Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in mg/dL
- Male CrCl = (140 - age in years) x weight in kg x 1.00 72 serum creatinine in mg/dL
- AST/ALT ≤ 3 x ULN
- Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert Syndrome, who can have total bilirubin < 3.0 mg/dL)
Women of childbearing potential (WOCBP) should have a negative serum pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the start of Nivolumab, because the effects of NeoVax plus Montanide and Nivolumab on the developing human fetus are unknown
Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with study agents, breastfeeding should be discontinued if the mother is treated with Ipilimumab, Nivolumab and Personalized Neoantigen vaccine + Montanide.
Female participants enrolled in the study, who are not free from menses for >2 years, post hysterectomy / oophorectomy, or surgically sterilized, should be willing to use either 2 adequate barrier methods or a barrier method plus a hormonal method of contraception to prevent pregnancy or to abstain from sexual activity throughout the study, starting with visit 1 through 23 weeks (30 days plus the time required for Nivolumab to undergo five half-lives) after the last dose of study therapy. Approved contraceptive methods include for example: intra uterine device, diaphragm with spermicide, cervical cap with spermicide, male condoms, or female condom with spermicide. Spermicides alone are not an acceptable method of contraception
Male participants should agree to use an adequate method of contraception starting with visit 1 through 31 weeks after the last dose of study therapy

Exclusion Criteria

Prior immunotherapy for metastatic melanoma except anti-CTLA-4
Concomitant therapy with any anti-cancer agents, other investigational anti-cancer therapies, or immunosuppressive agents including but not limited to methotrexate, chloroquine, azathioprine, etc. within six months of study participation
Active brain metastases or leptomeningeal metastases
Use of a non-oncology vaccine therapy for prevention of infectious diseases during the 4 week period prior to first dose of Nivolumab. Participants may not receive any non-oncology vaccine therapy during the period of Nivolumab or NeoVax plus Montanide administration and until at least 8 weeks after the last dose of study therapy
History of severe allergic reactions attributed to any vaccine therapy for the prevention of infectious diseases
Active, known or suspected autoimmune disease. Subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger
A condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study drug administration. Inhaled or topical steroids and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
test positive for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection requiring treatment, symptomatic
Any underlying medical condition, psychiatric condition or social situation that in the opinion of the investigator would compromise study administration as per protocol or compromise the assessment of AEs
Planned major surgery
Pregnant women are excluded from this study because Nivolumab, personalized neoantigen peptides and poly-ICLC are agents with unknown risks to the developing fetus. Because there is an unknown but potential risk of adverse events in nursing infants secondary to treatment of the mother with Nivolumab, personalized neoantigen peptides and poly-ICLC, nursing women are excluded from this study
Individuals with a history of an invasive malignancy are ineligible except for the following circumstances: a) individuals with a history of invasive malignancy are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy; b) individuals with the following cancers are eligible if diagnosed and treated - carcinoma in situ of the breast, oral cavity or cervix, localized prostate cancer, basal cell or squamous cell carcinoma of the skin

Study & Design

Study Type: INTERVENTIONAL

Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Cohort 2: Nivolumab, NeoVax + Montanide, Ipilimumab 5.0 mg per injection site	Nivolumab (480 mg infusion)	* Patients will receive Nivolumab at a 480 mg flat dose I.V. infusion every 4 weeks (28 days) * Patients will receive NeoVax plus Montanide injection on weeks 12, 15, 18, and 21 * Patients will receive concurrent Ipilimumab (5.0 mg per injection site) on weeks 12, 15, 18, and 21
Cohort 1: Nivolumab, NeoVax + Montanide, Ipilimumab 2.5 mg per injection site	Nivolumab (480 mg infusion)	* Patients will receive Nivolumab at a 480 mg flat dose I.V. infusion every 4 weeks (28 days) * Patients will receive NeoVax plus Montanide injection on weeks 12, 15, 18, and 21 * Patients will receive concurrent Ipilimumab (2.5 mg per injection site) on weeks 12, 15, 18, and 21
Cohort 1: Nivolumab, NeoVax + Montanide, Ipilimumab 2.5 mg per injection site	NeoVax plus Montanide	* Patients will receive Nivolumab at a 480 mg flat dose I.V. infusion every 4 weeks (28 days) * Patients will receive NeoVax plus Montanide injection on weeks 12, 15, 18, and 21 * Patients will receive concurrent Ipilimumab (2.5 mg per injection site) on weeks 12, 15, 18, and 21
Cohort 1: Nivolumab, NeoVax + Montanide, Ipilimumab 2.5 mg per injection site	Ipilimumab	* Patients will receive Nivolumab at a 480 mg flat dose I.V. infusion every 4 weeks (28 days) * Patients will receive NeoVax plus Montanide injection on weeks 12, 15, 18, and 21 * Patients will receive concurrent Ipilimumab (2.5 mg per injection site) on weeks 12, 15, 18, and 21
Cohort 2: Nivolumab, NeoVax + Montanide, Ipilimumab 5.0 mg per injection site	NeoVax plus Montanide	* Patients will receive Nivolumab at a 480 mg flat dose I.V. infusion every 4 weeks (28 days) * Patients will receive NeoVax plus Montanide injection on weeks 12, 15, 18, and 21 * Patients will receive concurrent Ipilimumab (5.0 mg per injection site) on weeks 12, 15, 18, and 21
Cohort 2: Nivolumab, NeoVax + Montanide, Ipilimumab 5.0 mg per injection site	Ipilimumab	* Patients will receive Nivolumab at a 480 mg flat dose I.V. infusion every 4 weeks (28 days) * Patients will receive NeoVax plus Montanide injection on weeks 12, 15, 18, and 21 * Patients will receive concurrent Ipilimumab (5.0 mg per injection site) on weeks 12, 15, 18, and 21

Primary Outcome Measures

Name	Time	Method
Number of Participants With Dose-Limiting Toxicity (DLT)	7 weeks after first dose of NeoVax	DLT (Protocol Section 5.5) definition: 1. Grade 3 or 4 toxicity that is definitely, probably, or possibly related to administration of vaccine, excluding transient (≤ 72 hours) flu-like symptoms; grade 3 nausea, vomiting, diarrhea, or constipation that returns to grade 2 (or lower) within 48 hours; any grade 3 rash that resolves to grade 2 or lower within 14 days; any grade 3 endocrine abnormality that is corrected with hormonal therapy within 4 weeks. 2. Grade 3 or 4 abnormal laboratory value that is at least possibly related to the administration of vaccine lasting for more than 7 days and requires hospitalization or medical intervention. Excludes any grade 3 electrolyte abnormality that: lasts ≤ 72 hours, is not clinically complicated, and resolves spontaneously or responds to conventional medical intervention. 3. Any grade 3 or grade 4 toxicity that is considered, in the opinion of the Principal Investigator, to be dose-limiting. 4. Any death related to study treatment.

Secondary Outcome Measures

Name	Time	Method
Number of Patients With Objective Response	Up to 26 weeks after first administration of NeoVax	The number of patients who had a best response to therapy of complete or partial response, as assessed by RECIST (Response Evaluation Criteria in Solid Tumors, Version 1.1). Complete response (CR): Disappearance of all target lesions; Partial response (PR): At least a 30% decrease of the sum of the diameters of target lesions; Progressive disease (PD): At least 20% increase in the sum of the diameters of target lesions; Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.
Number of Patients With Disease Progression/Recurrence	Up to 2 years	Number of patients with unresectable disease who experience disease progression (PD), per RECIST 1.1, or who had resectable disease and who experience disease recurrence.